In The Claims

- 1. (currently amended) A bispecific immunoglobulin molecule that comprises a first binding domain comprising a first immunoglobulin variable region comprising V_L and V_H domains of monoclonal antibody cmHsp70.1 as produced by hybridoma cmHsp70.1, deposited with the DSMZ-Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH, Mascheroder Weg 1 b, D-38124 Braunschweig, Germany on November 14, 2003, and assigned Accession Number DSM ACC2629 or from V_L and V_H domains of monoclonal antibody cmHsp70.2 as produced by the hybridoma cmHsp70.2, deposited with the DSMZ-Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH on November 14, 2003, and assigned Accession Number DSM ACC2630 which binds cell surface membrane-bound heat shock protein 70 (Hsp) (Hsp70) and a second binding domain comprising a second immunoglobulin variable region comprising V_L and V_H domains which binds a member of the anti-apoptotic Bcl-2-associated athanogene (Bag) family, wherein the bispecific molecule is capable of specifically binding its target antigen on viable tumor cells.
- 2. (canceled)
- 3. (currently amended) The bispecific molecule of claim 1, wherein said <u>member of the Bag family</u> is Bag-4.
- 4. (currently amended) The bispecific molecule of claim 1, wherein said first binding domain binds to the C-terminal domain of the Hsp Hsp70 and said second binding domain binds to the C-terminal domain of Bag protein.
- 5. (cancelled).
- 6. (previously presented) The bispecific molecule of claim 1, which is a dimeric molecule.

- 7. (previously presented) The bispecific molecule of claim 1, which has at least one further functional domain.
- 8.-14. (cancelled)
- 15. (previously presented) The bispecific molecule of claim 7, wherein said further functional domain is a cytotoxic agent or a label.
- 16.-21. (cancelled)
- 22. 55. (cancelled)
- 56. (previously presented) The bispecific molecule of claim 4, wherein said first binding domain binds human Hsp70 at amino acid residues 454-461 or 450-463.
- 57. (previously presented) The bispecific molecule of claim 4, wherein said second binding domain binds human Bag-4 at amino acid residues 443-457.
- 58. (cancelled)